Hilkens NA, Algra A, Diener HC, et al. - Because bleeding complications may offset the benefit of antiplatelet drugs in patients at high risk of bleeding but a low risk of recurrent ischemic events, researchers sought to examine the net benefit of antiplatelet treatment according to an individuals’ bleeding risk. Thirty-seven thousand eighty-seven patients were involved in the analyses. According to baseline bleeding risk, there was no clear preference for either aspirin-dipyridamole or clopidogrel. The risk of recurrent ischemic events and major bleeding increases in parallel among patients with a transient ischemic attack or ischemic stroke who are enrolled in clinical trials of antiplatelet therapy. Antiplatelet therapy cannot be tailored solely on the basis of bleeding risk assessment.